1-8 of 8
Mark W. Drummond, PhD FRCPath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Tamas Masszi, MD, Elena Mishchenko, MD, Mark W. Drummond, PhD FRCPath, Eric Jourdan, MD, Alessandro M. Vannucchi, MD, Mindaugas Jurgutis, Vincent Ribrag, MD, Alessandro Rambaldi, MD PhD, Liang Piu Koh, MBBS, MRCP, Shelonitda Rose, MD, Jun Zhang, PhD, Claire Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–12.
https://doi.org/10.1182/blood-2020-137279
Published: 2020
Journal Articles

Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

Charlotte K Brierley, MRCP, MD, Alba Rodriguez-Meira, PhD, Matthew Bashton, PhD, Angela Hamblin, MD PhD, Rachel S Fletcher, PhD, Sonia Fox, Charlotte Gaskell, BSc, MSc, Aimee Jackson, BSc, MSc, Jennifer O'Sullivan, MD, Lauren C Murphy, Nikolaos Sousos, MDMSc, Amir Enshaei, PhD, Claire Harrison, DM, FRCP, FRCPath, Mark W. Drummond, PhD FRCPath, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Bethan Psaila, MD PhD, Adam J. Mead, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-139520
Published: 2020
Journal Articles

Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms - Results of the Tamarin Study

Claire Harrison, DM, FRCP, FRCPath, Joanna Baxter, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Thomas McKerrell, MD PhD, Aimee Jackson, BSc, MSc, Rachel S Fletcher, PhD, Adam J. Mead, MD PhD, Steve Knapper, BMBCh, MRCP, FRCPath, DM, Joanne Ewing, MD PhD, Nauman M Butt, MD, Manish Jain, MBBS, MRCP, FRCpath, Sebastian Francis, MBChB, FRCPath, MD, Fiona J Clark, FRCP, FRCPath, Jason Coppell, MBBS, Mary Frances McMullin, MDFRCP, FRCPath, Frances Wadelin, MB ChB, PhD FRCPath, Srinivasan Narayanan, FRCP, FRCPath, Dragana Milojkovic, Mark W. Drummond, PhD FRCPath, Mallika Sekhar, MBBS, MD, Maike Paramor, James Roberts, BSc, Rachel Glover, BSc, Erica Harris, MSc, Luigi Grassi, PhD, Alba Rodriguez-Meira, PhD, Jason Carroll, PhD FMedSci, José-Ezequiel Martín, PhD, Giuditta Corbizi Fattori, PhD, Zijian Fang, BSc, Anna L Godfrey, BMBCh, PhD, Simón Méndez-Ferrer, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–35.
https://doi.org/10.1182/blood-2020-134764
Published: 2020
Journal Articles

Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study

Jason Gotlib, MD MS, Deepti H. Radia, MRCPI, FRCPath, Tracy I. George, MD, William A Robinson, MD PhD, Albert T. Quiery, MD, Mark W. Drummond, PhD FRCPath, Prithviraj Bose, MD, Elizabeth O. Hexner, MD, Elliott F. Winton, MD, Hans-Peter Horny, Prof, Dr, Meera Tugnait, PhD, Oleg Schmidt-Kittler, PhD, Erica K. Evans, PhD, Hui-Min Lin, PhD, Brenton G. Mar, MD PhD, Michael W. Deininger, MD PhD, Daniel J. DeAngelo, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-137413
Published: 2020
Journal Articles

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

Mark W. Drummond, PhD FRCPath, Charlotte Gaskell, BSc, MSc, Claire Harrison, DM, FRCP, FRCPath, Adam J. Mead, MD PhD, Christina Yap, PhD CStat, Aimee E Jackson, BSc, MSc, Jennifer Byrne, FRCP, FRCPath, PhD, Fiona J Clark, FRCP, FRCPath, Srinivasan Narayanan, FRCP, FRCPath, David Bowen, MD, Tim C.P Somervaille, PhD FRCP, FRCPath, Emma Gudgin, MBBS, MRCP, FRCPath, PhD, Dragana Milojkovic, Rachel S Fletcher, PhD, Charlotte K Brierley, MRCP, MD, Steve Knapper, BMBCh, MRCP, FRCPath, DM
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-138437
Published: 2020
Journal Articles

Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine

Karen Yee, MD, Giovanni Martinelli, MD, Sarit Assouline, MD, Margaret Kasner, MD, Norbert Vey, MD PhD, Kevin R. Kelly, MD, PhD, Mark W. Drummond, PhD, FRCPath, MB, CHB, Michael Dennis, FRCP, FRCPath, Karen Seiter, MD, Steven Blotner, PhD, Lori Jukofsky, Steven Middleton, PhD, Jianguo Zhi, PhD, Gong Chen, PhD, Hua Zhong, PhD, Gwen Nichols, MD
Journal: Blood
Blood (2013) 122 (21): 498.
https://doi.org/10.1182/blood.V122.21.498.498
Published: 2013
Journal Articles

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Michael Andreeff, MD, PhD, Kevin R. Kelly, MD, Karen Yee, MD, Sarit Assouline, Roger Strair, MD, PhD, Leslie Popplewell, MD, David Bowen, Giovanni Martinelli, MD, Mark W. Drummond, PhD, FRCPath, MB, CHB, Paresh Vyas, MD, Mark Kirschbaum, MD, Swaminathan Padmanabhan Iyer, MD, Kensuke Kojima, MD, PhD, David Geho, MD, Steven Blotner, PhD, Suzanne Cheng, PhD, Lyubomir Vassilev, PhD, Meichun Ding, PhD, Jianguo Zhi, PhD, Steven Middleton, PhD, Gwen Nichols, MD
Journal: Blood
Blood (2012) 120 (21): 675.
https://doi.org/10.1182/blood.V120.21.675.675
Published: 2012
Journal Articles

Midostaurin a Multi-Targeted Oral Kinase Inhibitor in Systemic Mastocytosis: Report of An Open-Label Compassionate Use Program in the United Kingdom

Steven Knapper, DM MRCP FRCPath, Jonathan Cullis, Mark W. Drummond, PhD, FRCPath, MB, CHB, Roger Evely, Tamara Everington, Christine Hoyle, Lorna McLintock, MBChB, MD, MRCP, FRCPath, Christopher Poynton, DM, FRCP, FRCPath, Deepti Radia, MD
Journal: Blood
Blood (2011) 118 (21): 5145.
https://doi.org/10.1182/blood.V118.21.5145.5145
Published: 2011